Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Building method of acute hyperuricemia mouse model

A technology of hyperuricemia and mouse model, which is applied in pharmaceutical formulations, organic active ingredients, medical preparations containing active ingredients, etc., can solve the problems of low molding rate, increased mortality, etc. The effect of strong reproduction and easy feeding

Pending Publication Date: 2017-11-21
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Due to the complexity of uric acid metabolism, the same modeling agent, different administration routes, dosages and animal sources have a greater impact on hyperuricemia; if the dosage is too large, the mortality rate will increase; if the dosage is insufficient, the model will be formed low rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Building method of acute hyperuricemia mouse model
  • Building method of acute hyperuricemia mouse model
  • Building method of acute hyperuricemia mouse model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Experiment on effectiveness and dose-effect relationship of inosine-induced acute hyperuricemia in mice

[0047] Select 40 mice of 22-25g, half male and half male, and randomly divide them into 5 groups, 8 mice in each group, and inject inosine intraperitoneally according to the following doses: 100mg / kg, 400mg / kg, 500mg / kg, 600mg / kg kg, and the control group was an equal volume of normal saline. Take 0.5ml of blood from the tail vein at 0h, 0.5h, 1h, 2h, 4h, and 8h after medication, separate the serum, and measure the serum uric acid value with the phosphotungstic acid method. .

[0048] The results showed that compared with the control group, the uric acid value of the 100mg / kg, 400mg / kg, 500mg / kg, and 600mg / kg dosage groups of mice increased at 0.5h. Compared with the control group, the uric acid value in the 100mg / kg dose group of mice increased, but the increase was not large. The blood uric acid concentration of the 400mg / kg and 500mg / kg dose groups w...

Embodiment 2

[0052] Example 2: Application of Acute Hyperuricemia Mouse Model in the Screening of Drugs for Lowering Uric Acid - Effect of Allopurinol on Blood Uric Acid in Hyperuricemia Mice

[0053] Allopurinol is an inhibitor of xanthine oxidase and is currently a commonly used urate-lowering drug. The optimal dose of allopurinol for reducing the uric acid level in mice with hyperuricemia caused by oxonate potassium is 47.2 mg / kg, which is also reported in the literature. In order to further verify that this dose can also effectively reduce hyperuricemia caused by inosine For the uric acid value of mice, 24 normal ICR mice, 22-25g, half male and half male, were randomly divided into 3 groups, 8 animals in each group, injected intraperitoneally, respectively 400mg / kg inosine group, 400mg / kg muscle Glycoside+47.2mg / kg allopurinol group, equal volume of normal saline control group. At 0h, 1h, 2h, 4h, and 8h after administration, 0.5ml of blood was collected from the tail vein, the serum w...

Embodiment 3

[0058] Example 3: Preliminary Toxicity and Safety Research of Inosine on Mice:

[0059] In this embodiment, different groups of mice after the mouse effectiveness experiment and the dose-effect dependence experiment of the above-mentioned embodiment 1 were respectively tested (see Example 1 for experimental grouping: 40 mice of 22-25 g were selected, half male and half male, randomly divided into two groups) 5 groups, 8 rats in each group, intraperitoneal injection of inosine according to the following doses, the doses are: 100mg / kg, 400mg / kg, 500mg / kg, 600mg / kg, the control group is equal volume of normal saline), continuous observation for 15 On the first day, the animal poisoning and death conditions were recorded. The results showed that all the animals did not show any discomfort, moved freely, took water and food, and the urine and stool were normal, and the general condition was good. All animals were sacrificed 15 days after the intraperitoneal injection, and grossly d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to a building method of an acute hyperuricemia mouse model, and belongs to the technical field of model building. According to the method, inosine enterocoelia is injected into an ICR mouse at an injection amount of 400 to 500 mg / kg, thus obtaining the acute hyperuricemia mouse model. According to the building method, an acute hyperuricemia animal model is firstly built by inosine for an ICR mouse serving as a common experimental animal in a biomedical research. The model has a typical illness representation; quantity indexes have statistical significance; the model is a simple, feasible, reliable and practical technology; furthermore, the invention provides a hypeluricemia animal model obtained by simulating a human uric acid metabolism path, and the hypeluricemia animal model has an important significance for developing researches on relevant diseases.

Description

technical field [0001] The invention belongs to the technical field of model construction, and in particular relates to a method for constructing an acute hyperuricemia mouse model. Background technique [0002] Uric acid is the end product of purine metabolism in the human body. It is mainly produced by liver metabolism and excreted by the kidneys. Hyperuricemia (HUA) is an increase in the level of uric acid in the blood due to excessive production of uric acid by liver metabolism or decreased excretion of uric acid by the kidneys, or both, even higher than the saturation concentration of blood uric acid crystals ( >7.0mg / dl, equivalent to 416.5μmol / L) is a pathological state. In recent years, with the improvement of people's living standards and changes in dietary structure and living habits, the prevalence of hyperuricemia has increased year by year. Epidemiological research data show that the incidence of hyperuricemia and primary gout is on the rise , In China, the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/708
CPCA61K31/708
Inventor 唐东红王陈芸叶尤松李哲丽邱炳玲陈倩肖涵杨浩杨忠马开利鲁帅尧黄璋琼
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com